StockData
Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc. (TRVI) stock

TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$13.72+0.21 (+1.55%)

Close on Nov 19, 2026Market cap $1.95BP/E –Yield –

Trevi Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Trevi Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$52.87M. For fiscal 2025 it was -$42.10M. The highest annual figure on record is -$18.45M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$42.10M–
FY2024Dec 31, 2024-$38.29M–
FY2023Dec 31, 2023-$31.85M–
FY2022Dec 31, 2022-$28.33M–
FY2020Dec 31, 2020-$29.03M–
FY2019Dec 31, 2019-$23.10M–
FY2018Dec 31, 2018-$18.45M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$17.55M–
Q1 FY2026Mar 31, 2026-$16.79M–
Q4 FY2025Dec 31, 2025-$7.63M–
Q3 FY2025Sep 30, 2025-$10.89M–
Q4 FY2024Dec 31, 2024-$9.56M–
Q3 FY2024Sep 30, 2024-$9.56M–
Q4 FY2023Dec 31, 2023-$6.38M–
Q3 FY2023Sep 30, 2023-$7.30M–
Q2 FY2023Jun 30, 2023-$9.92M–
Q1 FY2023Mar 31, 2023-$8.25M–
Q4 FY2022Dec 31, 2022-$6.45M–
Q4 FY2020Dec 31, 2020-$8.93M–
Q3 FY2020Sep 30, 2020-$6.98M–
Q4 FY2019Dec 31, 2019-$6.20M–
Q3 FY2019Sep 30, 2019-$7.73M–
Q2 FY2019Jun 30, 2019-$5.06M–
Q1 FY2019Mar 31, 2019-$4.11M–
Q4 FY2018Dec 31, 2018-$4.82M–
Q3 FY2018Sep 30, 2018-$3.99M–
Q2 FY2018Jun 30, 2018-$5.62M–
Q1 FY2018Mar 31, 2018-$4.01M–

More Trevi Therapeutics figures

See a number that looks wrong?